Anti-rtk antibodies and uses thereof
Agonistic antibodies targeting FGFR2IIIb, FGFR1IIIb, and DDR1a activate their signaling pathways, addressing the need for therapeutic agents that stimulate tissue repair and regeneration, effectively treating conditions like pulmonary and skin fibrosis.
HK40135148APending Publication Date: 2026-07-17CHUGAI PHARMA CO LTD
Patent Information
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- CHUGAI PHARMA CO LTD
- Filing Date
- 2026-05-15
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
There is a significant medical need for the development of FGFR2 and FGFR1 agonists, as well as DDR1 agonists, to stimulate tissue repair and regeneration processes, as existing therapeutic agents primarily focus on inhibition rather than activation of these receptor tyrosine kinases.
Method used
Development of agonistic antigen-binding molecules, such as antibodies or fragments, that bind to FGFR2, FGFR1, and DDR1, specifically targeting FGFR2IIIb, FGFR1IIIb, and DDR1a, to activate their signaling pathways and promote tissue regeneration.
Benefits of technology
These molecules effectively activate FGFR2IIIb, FGFR1IIIb, and DDR1a signaling, providing therapeutic agents for treating tissue degenerative diseases and conditions like pulmonary and skin fibrosis.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000240_0000 
Figure 00000242_0000 
Figure 00000243_0000
Abstract
The present invention relates to RTK agonists, in particular FGFR2b agonists, FGFR1b agonists, and DDR1 agonists, and methods of using the same.
Need to check novelty before this filing date? Find Prior Art